Genetic disorders and insulinoma/glucagonoma.
Marini F, Giusti F, Brandi ML.
Endocr Relat Cancer. 2024 Apr 16;31(5):e230245. doi: 10.1530/ERC-23-0245. Print 2024 May 1.
Synchronous Insulinoma and Glucagonoma: A Review of the Literature.
Damaskos C, Dimitroulis D, Garmpi A, Antoniou EA, Kouraklis G, Psilopatis I, Mavri M, Diamantis E, Marinos G, Kyriakos G, Farmaki P, Patsouras A, Kontzoglou K, Garmpis N.
In Vivo. 2023 Nov-Dec;37(6):2402-2408. doi: 10.21873/invivo.13345.
Glucagonoma syndrome.
Bloom SR, Polak JM.
Am J Med. 1987 May 29;82(5B):25-36. doi: 10.1016/0002-9343(87)90424-4.
Glucagonoma syndrome: a review and update on treatment.
John AM, Schwartz RA.
J Eur Acad Dermatol Venereol. 2016 Dec;30(12):2016-2022. doi: 10.1111/jdv.13752. Epub 2016 Jul 16.
[Glucagonoma].
Shimazu S, Tsukada T.
Nihon Rinsho. 2011 Mar;69 Suppl 2:593-6.
Glucagonoma-Associated Rash.
Mountjoy L, Kollmorgen D.
N Engl J Med. 2017 Mar 9;376(10):e18. doi: 10.1056/NEJMicm1603135.
Glucagonoma-related necrolytic migratory erythema.
Bosch-Amate X, Riera-Monroig J, Iranzo Fernández P.
Med Clin (Barc). 2020 Nov 13;155(9):418-419. doi: 10.1016/j.medcli.2019.06.027. Epub 2019 Sep 9.
Glucagonoma tumors and syndrome.
Montenegro-Rodas F, Samaan NA.
Curr Probl Cancer. 1981 Dec;6(6):1-54. doi: 10.1016/s0147-0272(81)80014-1.
Glucagonoma and pseudoglucagonoma syndromes.
Schwartz RA.
Int J Dermatol. 1997 Feb;36(2):81-9. doi: 10.1046/j.1365-4362.1997.00042.x.
European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes.
Hofland J, Falconi M, Christ E, Castaño JP, Faggiano A, Lamarca A, Perren A, Petrucci S, Prasad V, Ruszniewski P, Thirlwell C, Vullierme MP, Welin S, Bartsch DK.
J Neuroendocrinol. 2023 Aug;35(8):e13318. doi: 10.1111/jne.13318. Epub 2023 Aug 14.
